Cargando…

Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal disease

The aim of this post hoc analysis was to describe the immunogenicity of the 20-valent pneumococcal conjugate vaccine (PCV20) in adults with chronic medical conditions or smoking that place them at increased risk of developing pneumococcal disease. Data from 2 phase 3, randomized, active-controlled,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sabharwal, Charu, Sundaraiyer, Vani, Peng, Yahong, Moyer, Lisa, Belanger, Todd J., Gessner, Bradford D., Jodar, Luis, Jansen, Kathrin U., Gruber, William C., Scott, Daniel A., Watson, Wendy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Pneumococcal – Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746485/ https://www.ncbi.nlm.nih.gov/pubmed/36368038 http://dx.doi.org/10.1080/21645515.2022.2126253

Ejemplares similares

Safety and immunogenicity of a multivalent pneumococcal conjugate vaccine given with 13-valent pneumococcal conjugate vaccine in healthy infants: A phase 2 randomized trial
por: Simon, Michael W., et al.
Publicado: (2023)

The 15-valent pneumococcal conjugate vaccine V114 induces cross-reactive antibodies against pneumococcal serotype 6C
por: Shi, Yaru, et al.
Publicado: (2023)

A randomized, open-label, phase 3 study evaluating safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in Chinese infants and children under 6 years of age
por: Chu, Kai, et al.
Publicado: (2023)

Safety and immunogenicity of a 15-valent pneumococcal conjugate vaccine in Japanese healthy infants: A Phase I study (V114-028)
por: Ishihara, Yasunori, et al.
Publicado: (2023)

Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in Japanese healthy adults: A Phase I study
por: Haranaka, Miwa, et al.
Publicado: (2023)

Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18–49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors
por: Hammitt, Laura L., et al.
Publicado: (2023)

Response to article by Johnna Perdrizet et al.,“Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants”
por: Gómez, Jorge A., et al.
Publicado: (2021)

Pneumonia hospitalizations and mortality in children 3 – 24-month-old in Nigeria from 2013 to 2020: Impact of pneumococcal conjugate vaccine ten valent (PHiD-CV-10)
por: Iliya, Jalo, et al.
Publicado: (2023)

Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years
por: Essink, Brandon, et al.
Publicado: (2021)

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination
por: Bhorat, As’ad E., et al.
Publicado: (2015)

3. Phase 3 Pivotal Evaluation of 20-valent Pneumococcal Conjugate Vaccine (PCV20) Safety, Tolerability, and Immunologic Noninferiority in Participants 18 Years and Older
por: Essink, Brandon, et al.
Publicado: (2020)

Safety of the 15-valent pneumococcal conjugate vaccine: A phase I clinical trial
por: Pan, Lu-Lu, et al.
Publicado: (2022)

Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in Korea and Hong Kong
por: Mohanty, Salini, et al.
Publicado: (2022)

Exploring the evidence behind the comparable impact of the pneumococcal conjugate vaccines PHiD-CV and PCV13 on overall pneumococcal disease
por: Izurieta, Patricia, et al.
Publicado: (2021)

Cost-effectiveness analysis of PCV20 to prevent pneumococcal disease in the Canadian pediatric population
por: Lytle, Derek, et al.
Publicado: (2023)

Regional factors associated with pneumococcal vaccination coverage among U.S. adults with underlying chronic or immunocompromising conditions
por: Liu, Junqing, et al.
Publicado: (2023)

Surveillance of adverse events following immunization of 13-valent pneumococcal conjugate vaccine among infants, in Zhejiang province, China
por: Hu, Yu, et al.
Publicado: (2022)

A pediatric case series of invasive pneumococcal disease caused by S.Pneumonia serotype-19A despite full dose vaccination
por: Cura Yayla, Burcu Ceylan, et al.
Publicado: (2023)

Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine Coadministered with a Quadrivalent Influenza Vaccine in Adults 50 Years and Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
por: Baxter, Roger, et al.
Publicado: (2015)

Systematic review of the efficacy, effectiveness and impact of high-valency pneumococcal conjugate vaccines on otitis media
por: Izurieta, Patricia, et al.
Publicado: (2022)

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered in a prime-boost regimen among Chinese infants: a randomized, double blind phase III clinical trial
por: Wang, Wenjuan, et al.
Publicado: (2022)

Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults
por: Schmoele-Thoma, Beate, et al.
Publicado: (2019)

Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged ≥50 years: a randomized phase 3 trial (PNEU-FLU)
por: Severance, Randall, et al.
Publicado: (2021)

Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants in the United States
por: Senders, Shelly, et al.
Publicado: (2021)

Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age
por: Hurley, Donald, et al.
Publicado: (2020)

Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial
por: Thompson, Allison R., et al.
Publicado: (2018)

Immunogenicity, Safety, and Tolerability of 13-Valent Pneumococcal Conjugate Vaccine Followed by 23-Valent Pneumococcal Polysaccharide Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant Aged ≥2 Years: An Open-Label Study
por: Cordonnier, Catherine, et al.
Publicado: (2015)

Impact after 10-year use of pneumococcal conjugate vaccine in the Brazilian national immunization program: an updated systematic literature review from 2015 to 2020
por: Guzman-Holst, Adriana, et al.
Publicado: (2021)

1236. Safety and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Healthy Infants in the United States
por: Senders, Shelly, et al.
Publicado: (2020)

Pneumonia hospitalizations of children aged <2 years in Poland before (2013–2016) and after (2017–2018) universal mass vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine
por: Bhavsar, Amit, et al.
Publicado: (2022)

A narrative review on vaccination rate and factors associated with the willingness to receive pneumococcal vaccine in Chinese adult population
por: Yunhua, Bai, et al.
Publicado: (2022)

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults
por: Shiramoto, Masanari, et al.
Publicado: (2015)

Economic burden of pneumococcal disease in children in Liguria, Italy
por: Amicizia, Daniela, et al.
Publicado: (2022)

Pneumococcal serotypes in adults hospitalized with community-acquired pneumonia in Greece using urinary antigen detection tests: the EGNATIA study, November 2017 – April 2019
por: Liapikou, Adamantia, et al.
Publicado: (2022)

Impact of pneumococcal conjugate vaccines on healthcare utilization and direct costs for otitis media in children ≤2 years of age in two Swedish regions
por: Edmondson-Jones, Mark, et al.
Publicado: (2021)

Recommendations and Health Technology Assessment (HTA) landscape evaluation for pediatric pneumococcal conjugate vaccines (PCV) in Europe: A systematic literature review
por: Bencina, Goran, et al.
Publicado: (2022)

1240. Persistence of Circulating Antibody Through 12 Months Following Vaccination With a 20-Valent Pneumococcal Conjugate Vaccine in Adults 60–64 Years of Age
por: Hurley, Donald, et al.
Publicado: (2020)

The impact of COVID-19 on routine vaccinations in Taiwan and an unexpected surge of pneumococcal vaccination
por: Chiu, Nan-Chang, et al.
Publicado: (2022)

2711. Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease in Older Adults
por: Lewis, Ned, et al.
Publicado: (2019)

Factors influencing acceptance of influenza and pneumococcal vaccinations for patients with chronic obstructive pulmonary disease
por: Saiphoklang, Narongkorn, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_po4r4rs2jompp9mpfh9crkj8mv